Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Nucala® (mepolizumab) – Expanded indication
September 12, 2019 - GlaxoSmithKline announced the FDA approval of Nucala (mepolizumab), add-on maintenance treatment of patients with severe asthma aged 6 years and older, and with an eosinophilic phenotype.
